UBS upgraded its Momenta Pharmaceuticals MNTA rating from Neutral to Buy and trimmed its Momenta Pharmaceuticals price target from $17 to $16 in a research report published today.
Shares of Momenta Pharmaceuticals were trading at $11.37 at the time of posting, up 1.25% from Thursday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
